Core Viewpoint - The company, Jindalai (688057.SH), is optimistic about the development prospects of stem cell technology and plans to optimize its industrial structure to seek new opportunities for growth and enhance its risk resistance [1] Group 1: Investment and Strategic Moves - The company intends to invest 280 million yuan in Yunnan Jici Medical Technology Co., Ltd. (referred to as "Jici Medical") [1] - Upon completion of the transaction, the company will hold a 34% stake in Jici Medical [1] Group 2: Business Focus - The main business of Jici Medical and its subsidiaries is the research and application of autologous cell technology [1]